Home Biosimilar Antibodies Immunology & Inflammation CD markers Enoblituzumab (Anti-B7-H3 / CD276)
For research use only. Not for use in humans.

Enoblituzumab (Anti-B7-H3 / CD276)

Synonyms: MGA271

Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.

Enoblituzumab (Anti-B7-H3 / CD276)

Quality Control

Batch: Purity: 99% Protein concentration: 4.37mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.
References

Product Details

CAS No. 1353485-38-7
Molecular Weight 150
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07408063 RECRUITING Drug: GSK5764227|Drug: Dostarlimab Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma University Health Network, Toronto 2026-04-27 PHASE2
NCT05142189 RECRUITING Drug: Docetaxel|Drug: Carboplatin|Drug: Paclitaxel Non-Small Cell Lung Cancer BioNTech SE 2022-06-17 PHASE1
NCT04432649 NOT_YET_RECRUITING Solid Tumor Shenzhen Geno-Immune Medical Institute 2027-06-01 PHASE1; PHASE2
NCT04637503 NOT_YET_RECRUITING Neuroblastoma Shenzhen Geno-Immune Medical Institute 2026-12-31 PHASE1; PHASE2
NCT06014255 ACTIVE_NOT_RECRUITING Drug: Enoblituzumab Prostate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2024-02-16 PHASE2
NCT07231081 RECRUITING Solid Tumors Tcelltech Inc. 2025-10-16 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-04-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.